Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889657 | 0.89 | EPHX2 (0.65) | TRPV1EPHX2NR1H4NPC1CNR1 | |
| SCHEMBL4892768 | 0.84 | EPHX2 (0.66) | TRPV1EPHX2NR1H4NPC1RAB9A | |
| SCHEMBL3815572 | 0.82 | EPHX2 (0.67) | TRPV1EPHX2NR1H4 | |
| SCHEMBL4881016 | 0.81 | EPHX2 (0.53) | TRPV1EPHX2NR1H4 | |
| SCHEMBL4880784 | 0.81 | TRPV1 (0.62) | TRPV1EPHX2NR1H4 | |
| SCHEMBL4892103 | 0.81 | EPHX2 (0.52) | TRPV1EPHX2NR1H4 | |
| SCHEMBL3420620 | 0.74 | EPHX2 (0.65) | TRPV1EPHX2NR1H4NPC1RAB9A | |
| SCHEMBL4622881 | 0.73 | TRPV1 (0.56) | TRPV1EPHX2NR1H4 | |
| SCHEMBL4884181 | 0.73 | NR1H4 (0.49) | EPHX2NR1H4NPC1RAB9A | |
| SCHEMBL13167593 | 0.72 | TRPV1 (0.71) | TRPV1EPHX2NR1H4NPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071650-B2 | Vanilloid receptor modulators; analgesic, antiinflammatory and antiulcer effects; such as 1-(1H-indol-5-ylmethyl)-3-phenethylthiourea | PACIFIC CORPORATION (KR) | 2011-12-06 | — | — | US | disclosed |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | SUH YOUNG G | 2008-03-13 | — | — | US | disclosed |
| EP-1303483-A4 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORP (KR) | 2004-11-03 | — | — | EP | disclosed |
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | PACIFIC CORPORATION (KR) | 2003-08-14 | — | — | US | disclosed |
| EP-1303483-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002016318-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153596-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TAS2R40, TAS1R2, TAS2R45 | TRPV1 18/4885EPHX2 3810/4885NR1H4 690/4885 |
| US-20080064687-A1 | Novel thiourea derivatives and the pharmaceutical compositions containing the same | TRPV1, TRPA1, TAS2R5 | TRPV1 1/4885EPHX2 3840/4885NR1H4 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.